Vericel (VCEL) Projected to Post Earnings on Thursday

Vericel (NASDAQ:VCEL) is projected to release its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $72.6880 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:30 AM ET.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.03. Vericel had a net margin of 7.35% and a return on equity of 6.41%. The firm had revenue of $68.43 million during the quarter, compared to analysts’ expectations of $63.68 million. During the same period in the previous year, the company earned ($0.23) earnings per share. The firm’s quarterly revenue was up 30.1% on a year-over-year basis. On average, analysts expect Vericel to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Vericel Stock Performance

VCEL stock opened at $45.32 on Tuesday. The business’s 50-day moving average is $41.01 and its two-hundred day moving average is $37.18. The company has a market cap of $2.31 billion, a price-to-earnings ratio of 107.91 and a beta of 1.07. Vericel has a fifty-two week low of $28.95 and a fifty-two week high of $48.75.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on VCEL. HC Wainwright reissued a “buy” rating and issued a $64.00 target price on shares of Vericel in a report on Friday, May 8th. Wall Street Zen upgraded shares of Vericel from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Truist Financial lifted their target price on shares of Vericel from $42.00 to $54.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Finally, Weiss Ratings raised shares of Vericel from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 16th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $55.50.

Insiders Place Their Bets

In other Vericel news, CFO Joseph Anthony Mara, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $44.75, for a total value of $223,750.00. Following the completion of the transaction, the chief financial officer directly owned 16,009 shares in the company, valued at $716,402.75. This represents a 23.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Jonathan Mark Hopper sold 10,000 shares of Vericel stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $45.00, for a total transaction of $450,000.00. Following the sale, the insider owned 75,753 shares in the company, valued at approximately $3,408,885. The trade was a 11.66% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 47,732 shares of company stock valued at $2,084,167 in the last 90 days. 7.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Kestra Advisory Services LLC purchased a new position in shares of Vericel during the fourth quarter valued at about $27,000. Quarry LP bought a new position in Vericel during the fourth quarter valued at approximately $31,000. Truvestments Capital LLC grew its holdings in Vericel by 175.4% during the 4th quarter. Truvestments Capital LLC now owns 1,534 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 977 shares in the last quarter. Empowered Funds LLC purchased a new position in Vericel during the 4th quarter valued at approximately $58,000. Finally, Northwestern Mutual Wealth Management Co. increased its stake in Vericel by 48.2% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 3,019 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 982 shares during the last quarter.

About Vericel

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.